1. Home
  2. CASI vs SYBX Comparison

CASI vs SYBX Comparison

Compare CASI & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CASI Pharmaceuticals Inc.

CASI

CASI Pharmaceuticals Inc.

HOLD

Current Price

$0.96

Market Cap

24.9M

Sector

Health Care

ML Signal

HOLD

Logo Synlogic Inc.

SYBX

Synlogic Inc.

HOLD

Current Price

$1.03

Market Cap

15.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CASI
SYBX
Founded
1991
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.9M
15.2M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
CASI
SYBX
Price
$0.96
$1.03
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
30.5K
68.9K
Earning Date
11-14-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$26,846,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
21.72
N/A
52 Week Low
$0.93
$0.90
52 Week High
$3.97
$1.96

Technical Indicators

Market Signals
Indicator
CASI
SYBX
Relative Strength Index (RSI) 28.88 17.62
Support Level $0.93 $1.58
Resistance Level $1.25 $1.73
Average True Range (ATR) 0.09 0.10
MACD -0.01 -0.06
Stochastic Oscillator 8.91 2.67

Price Performance

Historical Comparison
CASI
SYBX

About CASI CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Share on Social Networks: